The Lesser Of

Seventh article in this silo. The tax treatment of a pharmacy is covered elsewhere on this site; this is about how the money arrives in the first place.

The Verdict, Stated First

Five claims, in descending order of confidence.

One. Ontario reimburses the lesser of the posted usual and customary fee and the ODB dispensing fee, which the province's own formulary states directly.

Two. That makes a pharmacy's cash price list a determinant of its public plan revenue, which is our reading of the provision and is the point of this article.

Three. The mark-up is 8 percent for drug costs under $1,000 and 6 percent at or above, on the government's own regulatory posting, and we found a pharmacy's website stating only the 6.

Four. A reconciliation adjustment reduces the sum of the dispensing fee and mark-up, by up to 4 percent on claims under $1,000 and up to 16 percent at or above.

Five. And we could not establish the current ODB dispensing fee, because the published figures do not agree and none of the ones we found was a government source.

The second is the one that changes a pricing decision, ours. A pharmacy competing on posted fee is bidding down its own government revenue, and nothing in the transaction announces that.

A Warning About Dates

Standing feature of this silo. Ours.

Four observations.

Everything here was verified on 29 August 2026 and drug reimbursement parameters are adjusted by regulation and by negotiation.

One of the two mark-up rates is under active review. The province has posted a proposal to replace the current framework with a multi-tiered structure[2], so the 8 and 6 percent figures may not survive.

The formulary itself is reissued frequently; the edition we consulted is dated September 2025[1].

And the structural point outlasts every number, ours. A lesser-of rule links two prices whatever their levels, and that linkage is what a pharmacy needs to understand.

Our Grades For These Claims

Applying the scheme this publication uses throughout.

Grade A for the reimbursement formula, taken from the Ontario Ministry of Health formulary[1].

Grade A for the mark-up rates and the reconciliation adjustment, both from Ontario government regulatory registry postings[2][3].

Grade D for the dispensing fee amount itself. Our sources disagree and none is a government publication, which is why we treat it as an assumption throughout.

Grade A for our own arithmetic, though it rests on that assumed fee and moves with it.

Grade C for the interprovincial comparison, which comes from a federal analytical study whose figures are several years old.

A Note On Method

Everything here is verified to 29 August 2026.

We obtained the Ontario Ministry of Health formulary, September 2025 edition, in extract[1], and two Ontario regulatory registry postings on the mark-up framework and the reconciliation adjustment[2][3].

We obtained a federal analytical study on dispensing fee policies in public drug plans[4].

We did not obtain Ontario Regulation 201/96 or the Ontario Drug Benefit Act, and cite them as the government postings describe them.

We could not find a government publication of the current ODB dispensing fee amount, and say so wherever the figure appears.

All arithmetic is ours. The pharmacy, its script volume, its public mix and its average drug cost are invented.

This article discusses a provincial reimbursement framework and is not accounting, legal, regulatory or pricing advice. A pharmacy should confirm current parameters with the Ministry and its own advisors.

What The Formulary Pays

The reimbursement formula, from the province's own document.

Pharmacies are "eligible to be reimbursed for the Drug Benefit Price (DBP) associated with the DIN or PIN, plus the applicable mark-up and the pharmacy's usual ODB dispensing fee, minus any applicable co-payment amount."[1]

Four observations, ours.

Three components, each governed separately. The drug price is set by the province, the mark-up by regulation, and the fee by a rule we come to next.

Only one of the three is within the pharmacy's control, and it is the one most often used as a competitive lever.

The co-payment is subtracted from what the province pays, not added, so it is a collection obligation rather than additional revenue.

And the Drug Benefit Price is the province's number, ours, which means acquisition cost above the DBP is absorbed by the pharmacy and acquisition below it is retained.

The Lesser Of

The provision this article is named for, in the formulary's own words.

Where a no-substitution prescription applies, "the dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount."[1]

Four observations, ours.

The pharmacy's posted cash fee caps its public reimbursement. Post below the ODB fee and you are paid your posted figure.

Post above it and there is no benefit, because the rule takes the lesser. The relationship is one-directional.

So the posted fee is a floor on nothing and a ceiling on everything, which is an unusual shape for a price to have.

And it means a cash pricing decision is a public revenue decision, ours, taken by whoever updates the sign in the window.

Which is a governance point as much as a pricing one, ours. In most pharmacies the posted fee is set by the owner or manager without reference to the claims file, and there is no step in that decision where the public revenue consequence is surfaced.

What That Costs

Our own arithmetic on an invented pharmacy. Every volume figure is ours; the fee is an assumption we flag.

Assume an ODB dispensing fee of $8.83. A pharmacy posting $11.99 or $9.99 is reimbursed $8.83, losing nothing. Posting $7.99 it is reimbursed $7.99, losing $0.84 a script. Posting $6.99: $1.84. Posting $4.49: $4.34.

Now take 40,000 scripts a year at a 60 percent public mix, being 24,000 ODB scripts. The annual cost of the posted fee is nil at $9.99 or above, $20,160 at $7.99, $44,160 at $6.99, $68,160 at $5.99 and $104,160 at $4.49.

Four observations.

The loss is invisible in the cash business, because it lands entirely on public claims that were already being filled at the higher rate.

It is also immediate and complete. There is no ramp; the day the posted fee drops, every subsequent public claim reimburses at the new figure.

And it scales with public mix rather than with the cash business the price cut is meant to win, ours, so the pharmacies most exposed are those most dependent on the public plan.

Which is an uncomfortable shape, because a pharmacy serving a low-income or senior population has the highest public mix and therefore the most to lose from competing on posted fee.

The Volume You Would Need

Our own arithmetic, expressing the same decision as a target.

If posting a lower fee costs public revenue, the new cash business has to replace it before the strategy makes any money.

At $7.99 posted, the $20,160 lost requires 2,523 additional scripts at $7.99 each. At $6.99: 6,318 additional scripts. At $5.99: 11,379.

Four observations.

6,318 scripts on a 40,000-script base is a 15.8 percent volume increase, and that is the break-even rather than the return.

The comparison also flatters the strategy, ours, because it credits the full posted fee to each new script and ignores the dispensing cost of filling it.

A commercial source puts the cost of dispensing a prescription in Ontario at over $15 today, against an estimate of $14 in 2006 before return on investment[6]. A pharmacy's own website rather than a study, flagged.

And if anything near that figure is right, ours, the additional scripts are loss-making individually, which turns a break-even target into an unreachable one.

Why The Chain Can Do It

The competitive asymmetry, which follows from the same arithmetic. Ours.

One source records a large warehouse retailer posting a dispensing fee of $4.49, against a range of roughly $8 to $16 described by a pharmacy researcher, and explains that some corporations lower dispensing fees to attract customers[7]. Another notes that larger retailers sometimes lose money intentionally on prescriptions as a loss leader[6].

Four observations, ours.

A retailer whose prescriptions exist to generate store traffic is playing a different game. The dispensing loss is a customer acquisition cost charged against grocery and general merchandise margin.

An independent pharmacy has no second margin pool to charge it against, so the same posted fee is simply a lower price.

The lesser-of rule then amplifies the asymmetry, because matching the posted fee also cuts the independent's public revenue, which is a larger share of its business.

And that is the strategic conclusion, ours. Matching on posted dispensing fee is the one competitive response an independent should be slowest to make, whatever the sign across the street says.

Nobody Agrees On The Fee

A sourcing problem we could not resolve, reported rather than papered over. Ours.

The published figures for the Ontario ODB dispensing fee: $8.83, stated as the government-paid fee[6]. Approximately $8.83 to $13.25, given as the range payable[5]. $8.40 since April 2012 for most pharmacies, with higher rural tiers[8]. And roughly $8 to $16, attributed to a pharmacy researcher as the range pharmacies charge[7].

Four observations.

We could not find the current figure in a government publication, which is why every calculation above is expressed against an assumption rather than a fact.

Some of the disagreement is definitional rather than factual. The ODB fee, the maximum a private plan pays, and what a pharmacy actually posts are three different numbers, and sources move between them without saying so.

The $8.40 figure is dated April 2012 by its own source, so it may simply be superseded.

And the arithmetic survives the uncertainty, ours, because the structure does not depend on the level. A reader should substitute the current figure and rerun it.

We would rather publish the gap than pick a number, ours. An article that quietly selected one of four disagreeing figures would have read as more authoritative and been less useful, since a pharmacy acting on the wrong one has the same problem we do.

The Rural Tiers

A feature worth knowing whichever base figure is current.

One source sets out higher fees where access is limited: $9.45 where there is only one pharmacy within 5 km, $11.55 where the nearest pharmacy is 5 to 10 km away, and $12.61 where it is 10 to 25 km[8].

A non-government site whose base figure appears dated, flagged, so treat the amounts as illustrative of the structure rather than as current.

Four observations, ours.

The tiers are keyed to distance from the next pharmacy, not to the pharmacy's own costs, which is a proximity test rather than a rurality test.

That has a consequence a rural operator should understand. A second pharmacy opening within the radius can move the incumbent to a lower tier, independent of anything the incumbent does.

It also interacts with the lesser-of rule in the same direction. A rural pharmacy entitled to a higher ODB fee loses more by posting a low cash fee, because the gap it forfeits is larger.

And that combination is worth modelling before a price move, ours, since the rural pharmacy is often the one under the most visible pressure to look competitive.

A Pharmacy Misstating Its Own Mark-Up

A second conflict, and this one has a clear right answer.

The Ontario government's regulatory posting states: "Claims for drug costs under $1,000 are eligible for an 8% mark-up, and claims for drug costs equal to or in-excess of $1,000 are eligible for a 6% mark-up." The framework is set out in Ontario Regulation 201/96 made under the Ontario Drug Benefit Act and was last updated in 2015[2].

A pharmacy's own website states that the ODB program "allows a 6% markup, which matches the 6% surcharge pharmacies pay to wholesalers."[6]

Four observations, ours.

The 6 percent rate applies only at drug costs of $1,000 or more. Community pharmacy claims are overwhelmingly below that.

So the statement is not merely imprecise. It describes the wrong tier for almost every prescription the pharmacy fills.

A consumer-facing source gets it right, for what it is worth, giving 6 percent at or above $1,000 and working an example at 8 percent on a $20 drug[7].

And the direction of the error is the interesting part, ours. The pharmacy understated its own reimbursement, in an article arguing that dispensing is underpaid, which is not the direction motivated error usually runs.

What The Two Points Are Worth

Our own arithmetic on the difference between the tiers.

At a drug cost of $20 the correct mark-up is $1.60 and 6 percent would give $1.20. At $100: $8.00 against $6.00. At $300: $24.00 against $18.00. At $800: $64.00 against $48.00. At $1,000 and above the two coincide, because 6 percent is correct there.

Taking an average ODB drug cost of $80, a figure one source gives for Ontario[6], the two percentage points are worth $1.60 a script, or $38,400 a year across our invented 24,000 public scripts.

Four observations.

This is a forecasting error rather than a cash loss. A pharmacy assuming 6 percent is being paid 8 and has simply understated its own revenue.

That still matters, ours, because a pharmacy that believes it earns less than it does will price and invest accordingly, and may accept terms it would otherwise refuse.

The tier boundary also creates a small discontinuity worth noticing. A $999 drug earns $79.92 of mark-up and a $1,000 drug earns $60.00, so the mark-up falls by nearly $20 as the drug cost rises by one dollar.

And the province has proposed replacing this structure, ours, with a multi-tiered framework said to benefit pharmacies processing mostly lower-cost claims[2], so the boundary may not persist.

The Adjustment Almost Nobody Models

A third component, and the one least discussed in anything we read.

A government posting describes a Pharmacy Reconciliation Adjustment reducing pharmacy payments: "The amount reduced is a percentage of the sum of the dispensing fee and mark-up paid to pharmacies based on the cost of the drug dispensed, as follows: up to 16% for drug costs equal to or over $1,000; and up to 4% for drug cost under $1,000."[3]

Four observations, ours.

It applies to the sum of the fee and the mark-up, being precisely the two components a pharmacy counts as its margin.

On our invented average script, a drug cost of $80 produces a fee of $8.83 plus mark-up of $6.40, a total of $15.23, reduced by up to 4 percent to $14.62. Across 24,000 public scripts that is $14,621 a year at the maximum rate.

The words "up to" are doing work we could not resolve, ours, and we did not establish what determines the actual rate applied or whether the adjustment remains in effect.

And the posting we obtained concerns an extension of the adjustment[3], which tells us it was in place and was being continued, and does not tell us its current status.

How The Three Stack

Putting them together, because they act on the same revenue. Ours.

On our invented pharmacy, three effects: the posted fee sitting below the ODB fee at $44,160; the mark-up understatement at $38,400; and the reconciliation adjustment at $14,621.

Four observations.

Only two of the three are cash. The posted fee and the adjustment reduce what arrives; the mark-up item is a forecasting error in the pharmacy's favour.

They are nonetheless best modelled together, because a pharmacy that has all three wrong has a materially incorrect picture of its own unit economics, in both directions at once.

The net of the three on our figures is a pharmacy earning less cash than it thinks on the fee and adjustment and more than it thinks on the mark-up, which is the worst kind of error because the offsets disguise each other.

And none of them appears as a line item, ours. All three arrive netted inside a claim payment, which is why they can persist for years.

The remedy is to rebuild a single claim by hand, ours. Take one paid claim, compute the Drug Benefit Price, the mark-up and the fee separately, and compare the total to what was actually received, which surfaces all three at once.

The Hundred-Day Supply

A structural feature of the fee model with a direct volume consequence.

The fee structure encourages the provision of a 100-day supply for most prescriptions under the ODB program, supporting adherence by reducing visit frequency, with pharmacists considering patient stability and medication type when setting supply duration[5].

Four observations, ours.

A dispensing fee is earned per fill, not per day supplied, so a 100-day supply earns one fee where three 30-day supplies would earn three.

That aligns the public payer's interest with the patient's and against the pharmacy's revenue, which is the intended design rather than an oversight.

It also means fee revenue is not a function of patients or prescriptions but of fills, and a pharmacy modelling growth on patient count is modelling the wrong denominator.

And it interacts with the inventory risk a pharmacy already carries, ours. Larger fills mean larger quantities leaving inventory per fee earned, which matters given what happens to unsold stock.

One source illustrates that risk concretely, ours: a $700 bottle of 100 tablets from which only 90 are sold recovers $630, and against a dispensing profit under $15 the pharmacy is out $55 on the bottle[6]. A single pharmacy's own worked example rather than data, flagged, but the shape of the exposure is right.

Two Years And Recovery

The compliance obligation attached to all of the above.

The formulary provides that "pharmacy documentation must be maintained in a readily available format for the purpose of post-payment verification for a minimum of 2 years" and that "overpayments due to inappropriate claim submissions are subject to recovery."[1]

Four observations, ours.

Post-payment verification is the operative concept. Payment is not acceptance, and a claim paid today can be examined later.

Two years is a minimum rather than a period, and the wording does not obviously cap the recovery window at two years.

The phrase "readily available format" is a storage standard as well as a retention one, so archived records that cannot be produced quickly may not satisfy it.

And this is where the earlier sections acquire teeth, ours. A pharmacy claiming a dispensing fee above its posted usual and customary fee has submitted a claim inconsistent with the formulary, and recovery is the stated consequence.

Why The Model Looks Like This

Brief history, because it explains the architecture.

In 2006 the Ontario legislature considered the Transparent Drug System for Patients Act, and committee hearings were "rocked" by revelations about rebates to pharmacies from generic manufacturers. A pharmacists' association calculation put the ODB program's share of generic spending affected at $228 million in 2005, against $1.6 billion spent on generics in Ontario's public and private markets that year. One witness speculated that the size of rebates, banned in the United States, went a long way toward explaining why Canada had the most expensive generic drugs in the developed world on the Patented Medicine Prices Review Board's assessment[9].

Four observations, ours.

The current architecture is a response to that. A transparent posted fee, a regulated mark-up and a set drug price replace a system where the real margin sat in undisclosed rebates.

Which explains why the mark-up is described as covering wholesaler mark-up and inventory carrying charges[2], that being the cost the rebates had previously offset.

The article we obtained is from 2006 and is history rather than current law, flagged, and we did not trace what became of every element of that legislation.

And it makes the lesser-of rule legible, ours. A posted fee only functions as a transparency device if the payer is entitled to it, which is exactly what the rule accomplishes.

Outside Ontario

A short comparison from a federal study, with its age flagged.

A Patented Medicine Prices Review Board analytical study on dispensing fee policies records that Alberta's pharmacy funding framework allows a dispensing fee of $12.15 effective May 2018, with limits on daily and frequent dispensing; that pharmacies in one province may charge up to $30 per prescription, or up to $60 for a sterile compound, regardless of the drug's base cost; and that in another the professional fee is defined by regulation as "the amount regularly charged by a pharmacist to persons who are responsible for paying the fee without reimbursement."[4]

Four observations, ours.

That last definition is the same idea as Ontario's lesser-of rule, expressed as a definition rather than as a comparison, and it produces the same linkage between cash price and public reimbursement.

So this is not an Ontario peculiarity. A pharmacy in more than one province should expect its posted price to matter in each.

The study is dated 2021/22 and its Alberta figure is from 2018[4], so the amounts are historical.

And we did not research any province in its own right, ours, which makes this a signpost rather than a comparison.

If You Own A Pharmacy

Practical, and not pricing, accounting or regulatory advice. Ours.

Four points.

Treat your posted usual and customary fee as a public revenue decision. On the formulary's wording it caps what the province pays you on every eligible claim.

Model the volume you would need before cutting it. On our own invented figures a $1.84 reduction needed a 15.8 percent volume increase merely to break even, before the cost of dispensing those scripts.

Confirm which mark-up tier applies to your claims. It is 8 percent below $1,000 on the government's posting, and we found a pharmacy publicly stating 6.

And find out whether a reconciliation adjustment is currently applied to you, since it reduces the fee and mark-up together and we could not establish its present status.

If You Advise One

For our own profession. Ours.

Four points.

Reconcile claimed fee to posted fee. A pharmacy claiming above its posted usual and customary fee has a recovery exposure, and post-payment verification is expressly contemplated.

Rebuild the average claim from its three components rather than reading net receipts, because the fee, the mark-up and any adjustment arrive netted and move independently.

Check the record retention position against the two-year readily-available standard, which is a storage requirement as well as a retention period.

And do not benchmark against a published dispensing fee. We found four different figures and none from a government source.

The internal comparison is available and better, ours. A pharmacy's own average realised fee per claim, computed from its remittances, is the only figure that reflects its posted price, its tier and any adjustment at once.

What To Do

Understand that reimbursement is the lesser of your posted fee and the ODB fee. Posting lower cuts your public revenue; posting higher gains nothing.

Verify the current ODB dispensing fee with the Ministry. We could not find it in a government publication and the figures in circulation disagree.

Apply 8 percent mark-up below $1,000 and 6 percent at or above, and note the province has proposed replacing that structure.

Model the reconciliation adjustment, which reduces the sum of fee and mark-up by up to 4 percent below $1,000 and up to 16 percent at or above.

Model fills rather than patients or prescriptions, because the fee is earned per fill and the system encourages 100-day supplies.

Keep documentation for at least two years in a readily available format, since overpayments are subject to recovery.

Check your rural tier if you are the only pharmacy in a radius, and remember a new entrant can move you down one.

And do not match a warehouse retailer's posted fee. They are charging the loss against another margin pool and you are not.

The Limits Of This Analysis

Several caveats matter. This article discusses a provincial reimbursement framework and is not accounting, legal, tax, regulatory or pricing advice; a pharmacy should confirm current parameters with the Ministry of Health and its own advisors. All rules were verified on 29 August 2026, the formulary edition we consulted is dated September 2025, and the mark-up framework is under active review with a multi-tiered replacement proposed. We could not find a government publication of the current ODB dispensing fee amount. The four figures we found disagree, come from non-government sources, and in one case are dated 2012; every calculation in this article therefore rests on an assumed fee of $8.83 and moves with it, and a reader should substitute the current figure. We did not obtain Ontario Regulation 201/96 or the Ontario Drug Benefit Act, and cite them as the government registry postings describe them. We did not establish what determines the actual reconciliation adjustment rate within the stated maxima, nor whether the adjustment remains in effect; our source concerns an extension of it and is not current-state confirmation. The rural fee tiers come from a non-government site whose base figure appears superseded, and should be treated as illustrative of structure rather than as current amounts. The cost-of-dispensing figure of over $15, and the $80 average drug cost, come from a single pharmacy's own website, flagged, and both are load-bearing in our break-even discussion. The interprovincial comparison is from a federal study dated 2021/22 containing figures from 2018, and we researched no province in its own right. The 2006 material is history and we did not trace what became of the legislation described. All arithmetic is ours: the 40,000 scripts, the 60 percent public mix and every derived figure are invented to demonstrate a structure. And our characterisation of a pharmacy's website as misstating the mark-up rests on our reading that community claims are overwhelmingly under $1,000, which we did not verify with data.

Related Reading

Niche Industry Finance The Vacancy Factor Another sector where one parameter in a government formula decides the economics. Niche Industry Operational Finance The Denominator Problem A shop rate is costs divided by billable hours. Divide by the wrong hours and every quote is wrong. Three ordinary errors compound to a quote... Niche Industry Finance Per Loaded Mile, Not Per Mile Another case where published figures for a whole sector refused to agree.

Frequently Asked Questions

What does Ontario actually pay a pharmacy per prescription?

The Drug Benefit Price for the product, plus the applicable mark-up, plus a dispensing fee, minus any co-payment. The fee component is the lesser of the pharmacy's posted usual and customary fee and the ODB dispensing fee.

Why does lowering my posted fee cost me money?

Because the formulary reimburses the lesser of the two figures. Posting below the ODB fee means the province pays your posted figure on every eligible claim. On our own arithmetic, an invented 40,000-script pharmacy at 60 percent public mix posting $6.99 against an assumed $8.83 fee loses $44,160 a year.

How much new business would that need to replace?

On the same invented figures, 6,318 additional scripts, a 15.8 percent volume increase, purely to break even. That calculation credits the full posted fee to each new script and ignores the cost of dispensing it, so it flatters the strategy.

What is the ODB mark-up rate?

On the Ontario government's regulatory posting, 8 percent for drug costs under $1,000 and 6 percent at or above, under Ontario Regulation 201/96, last updated in 2015. We found a pharmacy's own website stating only the 6 percent rate, which is the wrong tier for almost every community prescription.

What is the reconciliation adjustment?

A reduction applied to the sum of the dispensing fee and mark-up, of up to 4 percent where the drug cost is under $1,000 and up to 16 percent where it is $1,000 or more. We could not establish what sets the rate within those maxima or whether it currently applies.

What is the current ODB dispensing fee?

We could not establish it. The figures we found were $8.83, a range of $8.83 to $13.25, $8.40 dated April 2012 with higher rural tiers, and a $8 to $16 range attributed to a researcher. None came from a government publication, so confirm it with the Ministry.

Should I match a large retailer's dispensing fee?

On our own reasoning, this is the competitive response an independent should be slowest to make. A warehouse retailer charges the dispensing loss against grocery and general merchandise margin as a customer acquisition cost. An independent has no second margin pool, and the lesser-of rule means matching also cuts its public plan revenue.

References

1. Ontario Ministry of Health, Ontario Drug Benefit Formulary/Comparative Drug Index, Edition 43, dated 17 September 2025, obtained in extract. Provides that pharmacies are generally eligible to be reimbursed for the Drug Benefit Price associated with the DIN or PIN, plus the applicable mark-up and the pharmacy's usual ODB dispensing fee, minus any applicable co-payment amount, and that the usual conditions for payment of a dispensing fee under the ODB program must be followed; that where a prescriber writes "No Substitution" or "No Sub" the dispenser will be reimbursed the Drug Benefit Price plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable co-payment; that for billing purposes pharmacy documentation must be maintained in a readily available format for the purpose of post-payment verification for a minimum of 2 years; and that overpayments due to inappropriate claim submissions are subject to recovery. Note: the Ontario Ministry of Health's own formulary and the primary source for the reimbursement formula and the lesser-of rule that this article is built on. ontario.ca
2. Government of Ontario regulatory registry, consultation posting on changing mark-ups paid to dispensers under the Ontario Drug Benefit Program. States that under the ODB program a mark-up is paid to pharmacies and dispensing physicians for supplying drug products to eligible recipients; that the mark-up is a percentage of the cost of the drug supplied and is intended to account for a dispenser's costs incurred within the distribution chain, such as wholesaler mark-up and inventory carrying charges; that the mark-up framework is set out in Ontario Regulation 201/96 made under the Ontario Drug Benefit Act and was last updated in 2015; that claims for drug costs under $1,000 are eligible for an 8% mark-up and claims for drug costs equal to or in excess of $1,000 are eligible for a 6% mark-up; that amendments to O. Reg. 201/96 are required to implement a new multi-tiered mark-up payment framework based on drug costs; that the proposed framework would have a positive impact on community and retail pharmacies processing mostly lower-cost claims and a neutral to minimal impact for specialty and hospital-affiliated outpatient pharmacies; and that the measure follows a Budget 2019 commitment between the ministry and the pharmacy sector on savings for ODB sustainability. Note: an Ontario government regulatory registry posting and our source for the 8 and 6 percent mark-up rates and the proposed replacement framework. ontariocanada.com
3. Government of Ontario regulatory registry, posting on the Pharmacy Reconciliation Adjustment Extension, stating that the amount reduced is a percentage of the sum of the dispensing fee and mark-up paid to pharmacies based on the cost of the drug dispensed, being up to 16% for drug costs equal to or over $1,000 and up to 4% for drug cost under $1,000. Note: an Ontario government regulatory registry posting and our only source for the reconciliation adjustment. It concerns an EXTENSION of the measure and is not confirmation of current status; we did not establish what sets the rate within the stated maxima. ontariocanada.com
4. Patented Medicine Prices Review Board, National Prescription Drug Utilization Information System analytical study, Dispensing Fee Policies in Public Drug Plans, 2021/22, supporting information. Records that effective 17 May 2018 Alberta's pharmacy funding framework allows a dispensing fee of $12.15 except for compounded prescriptions, diabetic supplies or nutritional products, with limitations on reimbursement for daily and frequent dispensing including a limit of three fees per day per patient for daily dispensing and two fees per medication per 28-day period for recurrent dispensing between 2 and 27 days, with exemptions for opioid dependence treatments and other categories; that pharmacies are able to charge provincial drug programs up to $30 per prescription or up to $60 for a sterile compound regardless of the drug's base cost; that a dispensing or professional fee is an all-inclusive fee reimbursing direct and indirect costs associated with dispensing, distribution and cognitive service functions including patient counseling and profit; and that under one province's Prescription Drugs Payment of Benefits Regulation the professional fee is defined as the amount regularly charged by a pharmacist to persons responsible for paying the fee without reimbursement. Note: a federal government analytical study. Figures are DATED, the study covering 2021/22 and its Alberta figure being from 2018. Used only for interprovincial signposting. canada.ca
5. Pharmacy website explainer on the dispensing fee structure in Ontario pharmacies, June 2026, stating that dispensing fees are regulated primarily through the Ontario Drug Benefit Program and Ontario Regulation 201/96; that the range of dispensing fees payable under the ODB program typically falls between approximately $8.83 and $13.25 per prescription; and that the fee structure encourages the provision of a 100-day supply of medication for most prescriptions under the ODB program, supporting adherence by reducing visit frequency, with pharmacists considering patient stability and medication type when determining supply duration. Note: a pharmacy's commercial website, NOT a government source, flagged. One of four disagreeing figures for the dispensing fee. misterpharmacist.com
6. Independent pharmacy's own page on dispensing fees, dated 2025, stating that the government pays a dispensing fee of $8.83 and most private insurance plans pay a maximum dispensing fee of $11.99, though most pharmacies charge less due to competitive pressure; that larger retailers sometimes intentionally lose money on prescriptions as a loss leader; that the Ontario Drug Benefit program "allows a 6% markup, which matches the 6% surcharge pharmacies pay to wholesalers"; that in 2006 the average cost of dispensing a prescription in Ontario before return on investment was estimated at $14 and that today the cost accounting for overhead is over $15; that the average cost of the medicine in a prescription in Ontario is over $80, giving a gross profit of about 18 percent; and giving a worked example of expired stock in which a pharmacy recovers $630 of a $700 bottle and loses $55 net of a sub-$15 dispensing profit. Note: a single pharmacy's own website, NOT a government or research source, flagged. Cited for the $8.83 figure, the cost of dispensing, the $80 average drug cost, and for its 6 percent mark-up statement, which this article identifies as describing the wrong tier for community claims. centrumpharmacy.com
7. Consumer personal finance site's comparison of drug prices across Canadian pharmacy chains, November 2025, quoting a pharmacy researcher that the dispensing fee is where pharmacies have room to vary and could be anywhere from $8 up to $16, and that some corporations such as a warehouse retailer are willing to lower dispensing fees to attract customers, that retailer charging $4.49; stating that under the ODB the provincial government sets maximum drug cost or reimbursement prices for generic drugs and that pharmacies must follow regulations and cannot exceed the set maximum drug cost, markup and dispensing fee; that the ODB markup cap is 6 percent when total drug cost is equal to or greater than $1,000; and giving a worked example of a $20 ODB-covered drug with a markup of $1.60 at 8 percent plus a $10 dispensing fee totalling $31.60. Note: a consumer personal finance site, NOT a government source, flagged. Cited for the observed posted fees and because its mark-up example correctly applies the 8 percent tier. moosemoney.com
8. Independently published page on Ontario Drug Benefit dispensing fees, stating that there are two types of dispensing fee, the ODB fee and the usual and customary fee for prescriptions not claimed under ODB; that since April 2012 most pharmacies charge $8.40 for each ODB prescription filled except in rural areas; that higher fees apply where there is only one pharmacy within 5 km at $9.45, where the nearest pharmacy is 5 to 10 km away at $11.55, and where it is 10 to 25 km away at $12.61; and that ODB recipients pay usually $2 per prescription, or a $100 annual deductible with a $6.11 co-payment for seniors in the higher income bracket, with the province covering the remainder. Note: an independently published site, NOT a government source, flagged, and its base figure is dated April 2012 and may be superseded. Our only source for the rural tier structure, which we present as illustrative rather than current. odbdispensingfees.weebly.com
9. Silversides, A. (2006). Pharmacies receiving massive rebates from generic drug-makers. CMAJ, 175(4), 342. DOI 10.1503/cmaj.060904, PMID 16908889. Reports that revelations about rebates to pharmacies from generic manufacturers rocked committee hearings on Ontario's Transparent Drug System for Patients Act 2006; that the legislation aimed to achieve savings in the ODB program, then costing $3.4 billion a year, by allowing more interchangeability of generic drugs; that on a pharmacists' association calculation 40 percent of the ODB program's share of spending on generic drugs in 2005 amounted to $228 million, against $1.6 billion spent on generics in Ontario's public and private markets that year; that a witness speculated the size of rebates, banned in the United States, went a long way toward explaining why Canada had the most expensive generic drugs in the developed world on the Patented Medicines Prices Review Board's assessment; and that the bill amended the Ontario Drug Benefit Act and the Drug Interchangeability and Dispensing Fee Act. Note: a peer-reviewed medical journal news report, obtained in full. HISTORICAL, dated 2006, and cited only for the origin of the current framework. We did not trace what became of the legislation. CMAJ

This article discusses a provincial reimbursement framework and is not accounting, legal, tax, regulatory or pricing advice. The current ODB dispensing fee amount could not be found in a government publication; every calculation rests on an assumed figure and moves with it. The mark-up framework is under active review. All arithmetic is the authors' own and every pharmacy figure is invented.